A comparative study to know efficacy and safety of IM carbetocin verses IV carbetocin (drug to prevent PPH) in vaginal delivery
Not Applicable
Completed
- Conditions
- Health Condition 1: O80- Encounter for full-term uncomplicated delivery
- Registration Number
- CTRI/2023/03/050468
- Lead Sponsor
- DR SWATI TALWADE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 134
Inclusion Criteria
1.Patient consenting for study .
2.Term pregnancy (37 – 42 weeks of gestation) Expected to delivery vaginally
Exclusion Criteria
1.Elective cesarean section
2.Have known allergies to Carbetocin, other Oxytocin homologs or excipients in the medicinal products used in the trial;
3. Have cardiovascular disorders
4. Hypertensive disorders
5. Have hepatic or renal disease
6. Have epilepsy
7. Women with coagulopathies
8. Women having known conditions predisposing to atonic PPH like hydramnios,multiple gestations, and prolonged labor etc.
9.Are not willing to give consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of blood loss after administering Carbetocin both intramuscularly and intravenously <br/ ><br>By following criteria <br/ ><br>1.Blood loss by using caliberated drape . <br/ ><br> 2.pre and post hemoglobin levels and hematocrit (48hrs) <br/ ><br>Timepoint: blood loss after administration carbetocin immediately and 48hr after delivery
- Secondary Outcome Measures
Name Time Method .Assessment of cardiovascular changes after administering Carbetocin both intramuscularly and intravenously <br/ ><br>2. To assess the tone of uterus on scale of 1-5 <br/ ><br>3. Need for other uterotonics <br/ ><br>4. Need for any blood transfusion <br/ ><br>5. Retension of placenta <br/ ><br>Timepoint: 18 MONTHS